NLRP3 and COVID-19: Apart from colchicine and hydroxychloroquine, there are also other new or classic drugs that inhibit NLRP3 inflammasome and potentially effective to prevent the cytokine storms in COVID-19 patients (Zahid et al., 2019), including Tranilast and Oridonin.